click below
click below
Normal Size Small Size show me how
Seq. boost & SIB
Sequential boost
| Question | Answer |
|---|---|
| Sequential boost | - Involves high, intermediate and low dose PTV - Nodal areas can be high/low risk - PH1 dose constraints must NOT be met e.g. PH1: prostate and SV 56Gy in 28, PH2: prostate only 18Gy in 9 = 74Gy in 37 total |
| Triple phase sequential (prostate) | PH1: pelvic LNs, prostate and SVs 46Gy in 23 PH2: prostate and SVs 10Gy in 5 PH3: prostate only 18Gy in 9 = 74Gy in 39 total |
| Disadvantages of sequential boost | - Multiple plans - More QA requirements - More chances for error |
| 2 phase gynae | PH1: EBRT 50.4Gy in 28 PH2: brachy 16Gy in8 |
| 2 phase breast | PH1: 50Gy in 25 PH2: 16Gy in 8 |
| 2 phase H&N | PH1: 44Gy in 22 PH2: 16Gy in 8 = 60Gy in 30 |
| SIB | - Defines treatment delivering different doses per fraction to different target regions - Done via IMRT/VMAT |
| SIB prostate | PTV54: 54Gy in 37 PTV74: 74Gy in 37 |
| SIB H&N | PTV70: 70Gy in 35 PTV63: 63Gy in 35 PTV56: 56Gy in 35 |
| Benefits of SIB | - Only one plan for the entire treatment course (QA workflow benefits) - Better target conformity - Less dose to critical structures - Moderate treatment acceleration - Reduced total treatment time - Option for dose escalation |